# Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

> **NCT03547830** · PHASE2 · UNKNOWN · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 17 (estimated)

## Conditions studied

- Chronic Granulomatous Disease

## Interventions

- **DRUG:** Plerixafor
- **DRUG:** Gcsf

## Key facts

- **NCT ID:** NCT03547830
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-13
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2019-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03547830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03547830, "Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03547830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*